http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 13 Aug 2026 06:07:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Evotec+SE+++++++++++++++++For%3A+Aug+13/26915802.html si-local-file:///var/storage/secattach/20260813/26915802.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Evotec+SE+++++++++++++++++For%3A+Aug+13/26915802.html Thu, 13 Aug 2026 06:07:00 -0400 EVO EVT O.00233944 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Evotec+SE+++++++++++++++++For%3A+Aug+13/26915802.html si-local-file:///var/storage/secattach/20260813/26915802.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Evotec+SE+++++++++++++++++For%3A+Aug+13/26915802.html Thu, 13 Aug 2026 06:07:00 -0400 EVO EVT O.00233944 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Evotec+SE+++++++++++++++++For%3A+Aug+13/26915802.html si-local-file:///var/storage/secattach/20260813/26915802.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Evotec+SE+++++++++++++++++For%3A+Aug+13/26915802.html Thu, 13 Aug 2026 06:07:00 -0400 EVO EVT O.00233944 http://www.streetinsider.com/Corporate+News/Evotec+and+Odyssey+partner+on+autoimmune+drug+discovery/26877309.html <p>Evotec SE (NASDAQ: EVO) and Odyssey Therapeutics, Inc. (NASDAQ: ODTX) have entered an R&D collaboration to discover small molecule drug candidates for autoimmune and inflammatory diseases, according to a press release from Evotec.</p><p>Under the agreement, Odyssey will use Evotec's discovery platform, screening capabilities, and AI-enabled data science tools to identify and validate drug candidates across multiple disease targets. The collaboration pairs Odyssey's disease biology expertise with Evotec's compound libraries and high-throughput experimentation capabilities.</p><p>Evotec is eligible to receive milestone payments tied to the delivery of validated hit series for each target. Detailed financial terms were not disclosed.</p><p>Evotec Chief Scientific Officer Dr. http://www.streetinsider.com/Corporate+News/Evotec+and+Odyssey+partner+on+autoimmune+drug+discovery/26877309.html Thu, 06 Aug 2026 06:00:24 -0400 EVO EVT ODTX http://www.streetinsider.com/Corporate+News/Evotec+and+Odyssey+partner+on+autoimmune+drug+discovery/26877309.html <p>Evotec SE (NASDAQ: EVO) and Odyssey Therapeutics, Inc. (NASDAQ: ODTX) have entered an R&D collaboration to discover small molecule drug candidates for autoimmune and inflammatory diseases, according to a press release from Evotec.</p><p>Under the agreement, Odyssey will use Evotec's discovery platform, screening capabilities, and AI-enabled data science tools to identify and validate drug candidates across multiple disease targets. The collaboration pairs Odyssey's disease biology expertise with Evotec's compound libraries and high-throughput experimentation capabilities.</p><p>Evotec is eligible to receive milestone payments tied to the delivery of validated hit series for each target. Detailed financial terms were not disclosed.</p><p>Evotec Chief Scientific Officer Dr. http://www.streetinsider.com/Corporate+News/Evotec+and+Odyssey+partner+on+autoimmune+drug+discovery/26877309.html Thu, 06 Aug 2026 06:00:24 -0400 EVO EVT ODTX http://www.streetinsider.com/Corporate+News/Evotec+and+Odyssey+partner+on+autoimmune+drug+discovery/26877309.html <p>Evotec SE (NASDAQ: EVO) and Odyssey Therapeutics, Inc. (NASDAQ: ODTX) have entered an R&D collaboration to discover small molecule drug candidates for autoimmune and inflammatory diseases, according to a press release from Evotec.</p><p>Under the agreement, Odyssey will use Evotec's discovery platform, screening capabilities, and AI-enabled data science tools to identify and validate drug candidates across multiple disease targets. The collaboration pairs Odyssey's disease biology expertise with Evotec's compound libraries and high-throughput experimentation capabilities.</p><p>Evotec is eligible to receive milestone payments tied to the delivery of validated hit series for each target. Detailed financial terms were not disclosed.</p><p>Evotec Chief Scientific Officer Dr. http://www.streetinsider.com/Corporate+News/Evotec+and+Odyssey+partner+on+autoimmune+drug+discovery/26877309.html Thu, 06 Aug 2026 06:00:24 -0400 EVO EVT ODTX http://www.streetinsider.com/Press+Releases/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html <div class="xn-content"> <ul type="disc"><li>Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's discovery-stage programs</li><li>Evotec to deliver validated hit series across multiple high-value targets for large inflammatory and autoimmune diseases with high unmet medical need</li></ul><p><span class="legendSpanClass"><location value="LU/de..hambrg" idsrc="xmltag.org" >HAMBURG, Germany</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EVO" idsrc="xmltag.org" >Evotec SE</span> (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has entered a strategic R&amp;D collaboration with <span value="NASDAQ-NMS:ODTX" idsrc="xmltag.org" >Odyssey Therapeutics, Inc.</span> (NASDAQ: ODTX) to discover potential new treatments in autoimmune and inflammatory diseases.</p> <p>Under the agreement, http://www.streetinsider.com/Press+Releases/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html Thu, 06 Aug 2026 02:16:00 -0400 EVO EVT O.00233944 O.55938090 ODTX http://www.streetinsider.com/Press+Releases/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html <div class="xn-content"> <ul type="disc"><li>Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's discovery-stage programs</li><li>Evotec to deliver validated hit series across multiple high-value targets for large inflammatory and autoimmune diseases with high unmet medical need</li></ul><p><span class="legendSpanClass"><location value="LU/de..hambrg" idsrc="xmltag.org" >HAMBURG, Germany</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EVO" idsrc="xmltag.org" >Evotec SE</span> (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has entered a strategic R&amp;D collaboration with <span value="NASDAQ-NMS:ODTX" idsrc="xmltag.org" >Odyssey Therapeutics, Inc.</span> (NASDAQ: ODTX) to discover potential new treatments in autoimmune and inflammatory diseases.</p> <p>Under the agreement, http://www.streetinsider.com/Press+Releases/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html Thu, 06 Aug 2026 02:16:00 -0400 EVO EVT O.00233944 O.55938090 ODTX http://www.streetinsider.com/Press+Releases/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html <div class="xn-content"> <ul type="disc"><li>Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's discovery-stage programs</li><li>Evotec to deliver validated hit series across multiple high-value targets for large inflammatory and autoimmune diseases with high unmet medical need</li></ul><p><span class="legendSpanClass"><location value="LU/de..hambrg" idsrc="xmltag.org" >HAMBURG, Germany</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EVO" idsrc="xmltag.org" >Evotec SE</span> (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has entered a strategic R&amp;D collaboration with <span value="NASDAQ-NMS:ODTX" idsrc="xmltag.org" >Odyssey Therapeutics, Inc.</span> (NASDAQ: ODTX) to discover potential new treatments in autoimmune and inflammatory diseases.</p> <p>Under the agreement, http://www.streetinsider.com/Press+Releases/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html Thu, 06 Aug 2026 02:16:00 -0400 EVO EVT O.00233944 O.55938090 ODTX http://www.streetinsider.com/Press+Releases/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html <div class="xn-content"> <ul type="disc"><li>Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's discovery-stage programs</li><li>Evotec to deliver validated hit series across multiple high-value targets for large inflammatory and autoimmune diseases with high unmet medical need</li></ul><p><span class="legendSpanClass"><location value="LU/de..hambrg" idsrc="xmltag.org" >HAMBURG, Germany</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EVO" idsrc="xmltag.org" >Evotec SE</span> (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has entered a strategic R&amp;D collaboration with <span value="NASDAQ-NMS:ODTX" idsrc="xmltag.org" >Odyssey Therapeutics, Inc.</span> (NASDAQ: ODTX) to discover potential new treatments in autoimmune and inflammatory diseases.</p> <p>Under the agreement, http://www.streetinsider.com/Press+Releases/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html Thu, 06 Aug 2026 02:16:00 -0400 EVO EVT O.00233944 O.55938090 ODTX http://www.streetinsider.com/Press+Releases/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html <div class="xn-content"> <ul type="disc"><li>Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's discovery-stage programs</li><li>Evotec to deliver validated hit series across multiple high-value targets for large inflammatory and autoimmune diseases with high unmet medical need</li></ul><p><span class="legendSpanClass"><location value="LU/de..hambrg" idsrc="xmltag.org" >HAMBURG, Germany</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EVO" idsrc="xmltag.org" >Evotec SE</span> (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has entered a strategic R&amp;D collaboration with <span value="NASDAQ-NMS:ODTX" idsrc="xmltag.org" >Odyssey Therapeutics, Inc.</span> (NASDAQ: ODTX) to discover potential new treatments in autoimmune and inflammatory diseases.</p> <p>Under the agreement, http://www.streetinsider.com/Press+Releases/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html Thu, 06 Aug 2026 02:16:00 -0400 EVO EVT O.00233944 O.55938090 ODTX http://www.streetinsider.com/PRNewswire/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html <div class="xn-content"> <ul type="disc"><li>Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's discovery-stage programs</li><li>Evotec to deliver validated hit series across multiple high-value targets for large inflammatory and autoimmune diseases with high unmet medical need</li></ul><p><span class="legendSpanClass"><location value="LU/de..hambrg" idsrc="xmltag.org" >HAMBURG, Germany</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EVO" idsrc="xmltag.org" >Evotec SE</span> (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has entered a strategic R&amp;D collaboration with <span value="NASDAQ-NMS:ODTX" idsrc="xmltag.org" >Odyssey Therapeutics, Inc.</span> (NASDAQ: ODTX) to discover potential new treatments in autoimmune and inflammatory diseases.</p> <p>Under the agreement, http://www.streetinsider.com/PRNewswire/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html Thu, 06 Aug 2026 02:16:00 -0400 EVO EVT O.00233944 O.55938090 ODTX http://www.streetinsider.com/PRNewswire/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html <div class="xn-content"> <ul type="disc"><li>Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's discovery-stage programs</li><li>Evotec to deliver validated hit series across multiple high-value targets for large inflammatory and autoimmune diseases with high unmet medical need</li></ul><p><span class="legendSpanClass"><location value="LU/de..hambrg" idsrc="xmltag.org" >HAMBURG, Germany</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EVO" idsrc="xmltag.org" >Evotec SE</span> (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has entered a strategic R&amp;D collaboration with <span value="NASDAQ-NMS:ODTX" idsrc="xmltag.org" >Odyssey Therapeutics, Inc.</span> (NASDAQ: ODTX) to discover potential new treatments in autoimmune and inflammatory diseases.</p> <p>Under the agreement, http://www.streetinsider.com/PRNewswire/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html Thu, 06 Aug 2026 02:16:00 -0400 EVO EVT O.00233944 O.55938090 ODTX http://www.streetinsider.com/PRNewswire/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html <div class="xn-content"> <ul type="disc"><li>Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's discovery-stage programs</li><li>Evotec to deliver validated hit series across multiple high-value targets for large inflammatory and autoimmune diseases with high unmet medical need</li></ul><p><span class="legendSpanClass"><location value="LU/de..hambrg" idsrc="xmltag.org" >HAMBURG, Germany</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EVO" idsrc="xmltag.org" >Evotec SE</span> (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has entered a strategic R&amp;D collaboration with <span value="NASDAQ-NMS:ODTX" idsrc="xmltag.org" >Odyssey Therapeutics, Inc.</span> (NASDAQ: ODTX) to discover potential new treatments in autoimmune and inflammatory diseases.</p> <p>Under the agreement, http://www.streetinsider.com/PRNewswire/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html Thu, 06 Aug 2026 02:16:00 -0400 EVO EVT O.00233944 O.55938090 ODTX http://www.streetinsider.com/PRNewswire/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html <div class="xn-content"> <ul type="disc"><li>Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's discovery-stage programs</li><li>Evotec to deliver validated hit series across multiple high-value targets for large inflammatory and autoimmune diseases with high unmet medical need</li></ul><p><span class="legendSpanClass"><location value="LU/de..hambrg" idsrc="xmltag.org" >HAMBURG, Germany</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EVO" idsrc="xmltag.org" >Evotec SE</span> (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has entered a strategic R&amp;D collaboration with <span value="NASDAQ-NMS:ODTX" idsrc="xmltag.org" >Odyssey Therapeutics, Inc.</span> (NASDAQ: ODTX) to discover potential new treatments in autoimmune and inflammatory diseases.</p> <p>Under the agreement, http://www.streetinsider.com/PRNewswire/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html Thu, 06 Aug 2026 02:16:00 -0400 EVO EVT O.00233944 O.55938090 ODTX http://www.streetinsider.com/PRNewswire/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html <div class="xn-content"> <ul type="disc"><li>Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's discovery-stage programs</li><li>Evotec to deliver validated hit series across multiple high-value targets for large inflammatory and autoimmune diseases with high unmet medical need</li></ul><p><span class="legendSpanClass"><location value="LU/de..hambrg" idsrc="xmltag.org" >HAMBURG, Germany</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EVO" idsrc="xmltag.org" >Evotec SE</span> (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has entered a strategic R&amp;D collaboration with <span value="NASDAQ-NMS:ODTX" idsrc="xmltag.org" >Odyssey Therapeutics, Inc.</span> (NASDAQ: ODTX) to discover potential new treatments in autoimmune and inflammatory diseases.</p> <p>Under the agreement, http://www.streetinsider.com/PRNewswire/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html Thu, 06 Aug 2026 02:16:00 -0400 EVO EVT O.00233944 O.55938090 ODTX http://www.streetinsider.com/Corporate+News/Niagen+Bioscience+taps+Evotec+for+NB4168+preclinical+drug+studies/26854529.html <p>Niagen Bioscience, Inc. (NASDAQ: NAGE) has selected Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT) as a contract research organization to conduct preclinical studies for NB4168, its oral small-molecule candidate being developed for Ataxia Telangiectasia (A-T), a rare pediatric genetic disease with no approved treatments.</p><p>Under the agreement, Evotec will conduct pharmacokinetic and pharmacodynamic studies and validate bioanalytical methods to support Niagen Bioscience's preclinical and Investigational New Drug (IND)-enabling activities. The work will be conducted at Evotec's campus in Verona, Italy, using its INDiGO platform, which integrates drug product development, safety, absorption, distribution, metabolism, and excretion, and regulatory and clinical services.</p><p>The studies http://www.streetinsider.com/Corporate+News/Niagen+Bioscience+taps+Evotec+for+NB4168+preclinical+drug+studies/26854529.html Mon, 03 Aug 2026 08:33:14 -0400 EVO NAGE http://www.streetinsider.com/Corporate+News/Niagen+Bioscience+taps+Evotec+for+NB4168+preclinical+drug+studies/26854529.html <p>Niagen Bioscience, Inc. (NASDAQ: NAGE) has selected Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT) as a contract research organization to conduct preclinical studies for NB4168, its oral small-molecule candidate being developed for Ataxia Telangiectasia (A-T), a rare pediatric genetic disease with no approved treatments.</p><p>Under the agreement, Evotec will conduct pharmacokinetic and pharmacodynamic studies and validate bioanalytical methods to support Niagen Bioscience's preclinical and Investigational New Drug (IND)-enabling activities. The work will be conducted at Evotec's campus in Verona, Italy, using its INDiGO platform, which integrates drug product development, safety, absorption, distribution, metabolism, and excretion, and regulatory and clinical services.</p><p>The studies http://www.streetinsider.com/Corporate+News/Niagen+Bioscience+taps+Evotec+for+NB4168+preclinical+drug+studies/26854529.html Mon, 03 Aug 2026 08:33:14 -0400 EVO NAGE http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Selects+Global+Drug+Development+Pioneer+Evotec+to+Advance+Preclinical+Development+for+NB4168/26854513.html <p class="bwalignc"><i>Collaboration will support pharmacokinetic, pharmacodynamic, and bioanalytical studies for Niagen Bioscience’s lead investigational candidate for rare pediatric diseases</i></p><p class="bwalignc"><i>Evotec brings deep drug development expertise, serving leading pharmaceutical and biotechnology companies across the life sciences industry</i></p> <p> LOS ANGELES--(BUSINESS WIRE)--</p> <p class="bwalignl"><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54582068&amp;newsitemid=20260803679197&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=7bd8cd720fe423ff11fb01ea848f7c52" shape="rect">Niagen Bioscience, Inc.</a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has selected <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.evotec.com%2F&amp;esheet=54582068&amp;newsitemid=20260803679197&amp;lan=en-US&amp;anchor=Evotec&amp;index=2&amp;md5=3a5012b50e17966ab95fb81e1aa78403" shape="rect">Evotec</a> (NASDAQ: EVO; Frankfurt Prime Standard: EVT), a global life science company specializing in drug discovery and development, as a contract research http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Selects+Global+Drug+Development+Pioneer+Evotec+to+Advance+Preclinical+Development+for+NB4168/26854513.html Mon, 03 Aug 2026 08:32:00 -0400 A.06822034 EVO EVT NAGE O.00233944 O.02128141 O.20026344 http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Selects+Global+Drug+Development+Pioneer+Evotec+to+Advance+Preclinical+Development+for+NB4168/26854513.html <p class="bwalignc"><i>Collaboration will support pharmacokinetic, pharmacodynamic, and bioanalytical studies for Niagen Bioscience’s lead investigational candidate for rare pediatric diseases</i></p><p class="bwalignc"><i>Evotec brings deep drug development expertise, serving leading pharmaceutical and biotechnology companies across the life sciences industry</i></p> <p> LOS ANGELES--(BUSINESS WIRE)--</p> <p class="bwalignl"><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54582068&amp;newsitemid=20260803679197&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=7bd8cd720fe423ff11fb01ea848f7c52" shape="rect">Niagen Bioscience, Inc.</a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has selected <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.evotec.com%2F&amp;esheet=54582068&amp;newsitemid=20260803679197&amp;lan=en-US&amp;anchor=Evotec&amp;index=2&amp;md5=3a5012b50e17966ab95fb81e1aa78403" shape="rect">Evotec</a> (NASDAQ: EVO; Frankfurt Prime Standard: EVT), a global life science company specializing in drug discovery and development, as a contract research http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Selects+Global+Drug+Development+Pioneer+Evotec+to+Advance+Preclinical+Development+for+NB4168/26854513.html Mon, 03 Aug 2026 08:32:00 -0400 A.06822034 EVO EVT NAGE O.00233944 O.02128141 O.20026344 http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Selects+Global+Drug+Development+Pioneer+Evotec+to+Advance+Preclinical+Development+for+NB4168/26854513.html <p class="bwalignc"><i>Collaboration will support pharmacokinetic, pharmacodynamic, and bioanalytical studies for Niagen Bioscience’s lead investigational candidate for rare pediatric diseases</i></p><p class="bwalignc"><i>Evotec brings deep drug development expertise, serving leading pharmaceutical and biotechnology companies across the life sciences industry</i></p> <p> LOS ANGELES--(BUSINESS WIRE)--</p> <p class="bwalignl"><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54582068&amp;newsitemid=20260803679197&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=7bd8cd720fe423ff11fb01ea848f7c52" shape="rect">Niagen Bioscience, Inc.</a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has selected <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.evotec.com%2F&amp;esheet=54582068&amp;newsitemid=20260803679197&amp;lan=en-US&amp;anchor=Evotec&amp;index=2&amp;md5=3a5012b50e17966ab95fb81e1aa78403" shape="rect">Evotec</a> (NASDAQ: EVO; Frankfurt Prime Standard: EVT), a global life science company specializing in drug discovery and development, as a contract research http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Selects+Global+Drug+Development+Pioneer+Evotec+to+Advance+Preclinical+Development+for+NB4168/26854513.html Mon, 03 Aug 2026 08:32:00 -0400 A.06822034 EVO EVT NAGE O.00233944 O.02128141 O.20026344 http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Selects+Global+Drug+Development+Pioneer+Evotec+to+Advance+Preclinical+Development+for+NB4168/26854513.html <p class="bwalignc"><i>Collaboration will support pharmacokinetic, pharmacodynamic, and bioanalytical studies for Niagen Bioscience’s lead investigational candidate for rare pediatric diseases</i></p><p class="bwalignc"><i>Evotec brings deep drug development expertise, serving leading pharmaceutical and biotechnology companies across the life sciences industry</i></p> <p> LOS ANGELES--(BUSINESS WIRE)--</p> <p class="bwalignl"><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54582068&amp;newsitemid=20260803679197&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=7bd8cd720fe423ff11fb01ea848f7c52" shape="rect">Niagen Bioscience, Inc.</a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has selected <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.evotec.com%2F&amp;esheet=54582068&amp;newsitemid=20260803679197&amp;lan=en-US&amp;anchor=Evotec&amp;index=2&amp;md5=3a5012b50e17966ab95fb81e1aa78403" shape="rect">Evotec</a> (NASDAQ: EVO; Frankfurt Prime Standard: EVT), a global life science company specializing in drug discovery and development, as a contract research http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Selects+Global+Drug+Development+Pioneer+Evotec+to+Advance+Preclinical+Development+for+NB4168/26854513.html Mon, 03 Aug 2026 08:32:00 -0400 A.06822034 EVO EVT NAGE O.00233944 O.02128141 O.20026344 http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Selects+Global+Drug+Development+Pioneer+Evotec+to+Advance+Preclinical+Development+for+NB4168/26854513.html <p class="bwalignc"><i>Collaboration will support pharmacokinetic, pharmacodynamic, and bioanalytical studies for Niagen Bioscience’s lead investigational candidate for rare pediatric diseases</i></p><p class="bwalignc"><i>Evotec brings deep drug development expertise, serving leading pharmaceutical and biotechnology companies across the life sciences industry</i></p> <p> LOS ANGELES--(BUSINESS WIRE)--</p> <p class="bwalignl"><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54582068&amp;newsitemid=20260803679197&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=7bd8cd720fe423ff11fb01ea848f7c52" shape="rect">Niagen Bioscience, Inc.</a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has selected <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.evotec.com%2F&amp;esheet=54582068&amp;newsitemid=20260803679197&amp;lan=en-US&amp;anchor=Evotec&amp;index=2&amp;md5=3a5012b50e17966ab95fb81e1aa78403" shape="rect">Evotec</a> (NASDAQ: EVO; Frankfurt Prime Standard: EVT), a global life science company specializing in drug discovery and development, as a contract research http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Selects+Global+Drug+Development+Pioneer+Evotec+to+Advance+Preclinical+Development+for+NB4168/26854513.html Mon, 03 Aug 2026 08:32:00 -0400 A.06822034 EVO EVT NAGE O.00233944 O.02128141 O.20026344 http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Selects+Global+Drug+Development+Pioneer+Evotec+to+Advance+Preclinical+Development+for+NB4168/26854513.html <p class="bwalignc"><i>Collaboration will support pharmacokinetic, pharmacodynamic, and bioanalytical studies for Niagen Bioscience’s lead investigational candidate for rare pediatric diseases</i></p><p class="bwalignc"><i>Evotec brings deep drug development expertise, serving leading pharmaceutical and biotechnology companies across the life sciences industry</i></p> <p> LOS ANGELES--(BUSINESS WIRE)--</p> <p class="bwalignl"><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54582068&amp;newsitemid=20260803679197&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=7bd8cd720fe423ff11fb01ea848f7c52" shape="rect">Niagen Bioscience, Inc.</a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has selected <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.evotec.com%2F&amp;esheet=54582068&amp;newsitemid=20260803679197&amp;lan=en-US&amp;anchor=Evotec&amp;index=2&amp;md5=3a5012b50e17966ab95fb81e1aa78403" shape="rect">Evotec</a> (NASDAQ: EVO; Frankfurt Prime Standard: EVT), a global life science company specializing in drug discovery and development, as a contract research http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Selects+Global+Drug+Development+Pioneer+Evotec+to+Advance+Preclinical+Development+for+NB4168/26854513.html Mon, 03 Aug 2026 08:32:00 -0400 A.06822034 EVO EVT NAGE O.00233944 O.02128141 O.20026344 http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Selects+Global+Drug+Development+Pioneer+Evotec+to+Advance+Preclinical+Development+for+NB4168/26854513.html <p class="bwalignc"><i>Collaboration will support pharmacokinetic, pharmacodynamic, and bioanalytical studies for Niagen Bioscience’s lead investigational candidate for rare pediatric diseases</i></p><p class="bwalignc"><i>Evotec brings deep drug development expertise, serving leading pharmaceutical and biotechnology companies across the life sciences industry</i></p> <p> LOS ANGELES--(BUSINESS WIRE)--</p> <p class="bwalignl"><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54582068&amp;newsitemid=20260803679197&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=7bd8cd720fe423ff11fb01ea848f7c52" shape="rect">Niagen Bioscience, Inc.</a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has selected <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.evotec.com%2F&amp;esheet=54582068&amp;newsitemid=20260803679197&amp;lan=en-US&amp;anchor=Evotec&amp;index=2&amp;md5=3a5012b50e17966ab95fb81e1aa78403" shape="rect">Evotec</a> (NASDAQ: EVO; Frankfurt Prime Standard: EVT), a global life science company specializing in drug discovery and development, as a contract research http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Selects+Global+Drug+Development+Pioneer+Evotec+to+Advance+Preclinical+Development+for+NB4168/26854513.html Mon, 03 Aug 2026 08:32:00 -0400 A.06822034 EVO EVT NAGE O.00233944 O.02128141 O.20026344